Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teva can keep generic Protonix for now

This article was originally published in The Tan Sheet

Executive Summary

A federal court decision allows Teva Pharmaceutical Industries to continue marketing the generic Rx proton pump inhibitor pantoprazole. The U.S. Court of Appeals for the Federal Circuit affirmed the denial of a motion for a preliminary injunction filed by Wyeth and Altana against the generic equivalent to Wyeth's Protonix delayed-release tablets, the Jerusalem-based firm said May 14. Pantoprazole has received a positive opinion in the European Union for a switch to nonprescription status, and has been mentioned for possible OTC switch in the U.S. (1"The Tan Sheet" Feb. 4, 2008, p. 3). Teva launched generic pantoprazole in December 2007 and said it is still involved in patent litigation with Wyeth and Altana over the product

You may also be interested in...



OTC Switch Offers Firms Opportunities To Diversify Earnings – Morgan Stanley

Rx-to-OTC switches offer drug firms a "meaningful opportunity" to diversify their earnings, which is gaining importance in an "increasingly challenging pharmaceutical landscape" Morgan Stanley market analysts say

New EU Approvals

The Pink Sheet’s list of EU centralized approvals of new active substances has been updated with three new products including Novartis's Beovu for treating neovascular (wet) age related macular degeneration. The list, which contains information dating back to January 2018, includes brand name, generic name, company, therapeutic indication, date of marketing authorization and product type (eg, medicine, vaccine, biologic).

QUOTED. 21 February 2020. Nancy Messonnier.

The US Centers for Disease Control and Prevention is reformulating a reagent in a batch of COVID-19 tests due to inconsistent performance. See what CDC official Nancy Messonier had to say about it.

Topics

UsernamePublicRestriction

Register

PS102931

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel